Article - 30/08/2010 Bodensee Brustzentrum offers effective breast cancer prevention services The two Brustzentrum Bodensee (Lake Constance Breast Centre) sites at the Hospital in Constance and the Women’s Hospital in Friedrichshafen have a principal goal: to enable the best possible early detection of all types of breast cancer, to reduce the morbidity and mortality of breast cancer patients and to increase survival rates by offering ultra-modern breast cancer prevention measures. https://www.gesundheitsindustrie-bw.de/en/article/news/bodensee-brustzentrum-offers-effective-breast-cancer-prevention-services
Article - 30/08/2010 More effective prevention and treatment of diabetic feet Dr. med. dent. Hans-Helmut Schmidt has developed a device that enables the effective and hygienic treatment of patients with diabetic foot syndrome DFS. The new device known as DIAPEDES enables diabetic feet to be treated in a closed foot-shaped container under definite clinical conditions. Diabetic feet can smell and look quite unpleasant and the preventive care that this device will offer for many users has been developed with this problem in…https://www.gesundheitsindustrie-bw.de/en/article/news/more-effective-prevention-and-treatment-of-diabetic-feet
Press release - 12/08/2010 Glycotope Received Regulatory Approval for Glycooptimized and Fully Human Glycosylated Antibody CetuGEX™ and Enrolls First Patients in Clinical Trial Glycotope GmbH, a leading glycobiology company, has received regulatory approval by German and Italian regulatory authorities for a Phase I study of Glycotope´s next generation antibody CetuGEX™ (GT-MAB 5.2-GEX) for the treatment of various solid cancers. https://www.gesundheitsindustrie-bw.de/en/article/press-release/glycotope-received-regulatory-approval-for-glycooptimized-and-fully-human-glycosylated-antibody-cetu
Press release - 08/08/2010 Human protein produced in a moss bioreactor The research group led by Prof. Ralf Reski is a moss specialist and has now, for the first time, succeeded in producing a human protein in a moss bioreactor – the complement factor H. The lack of this protein leads to age-related macular degeneration in about 50 million people worldwide. The complement factor H has been assigned ‘orphan drug’ status by the respective EU authorities.https://www.gesundheitsindustrie-bw.de/en/article/press-release/human-protein-produced-in-a-moss-bioreactor
Press release - 02/08/2010 Stephanie Combs – excellent research on the treatment of brain tumours Dr. Stephanie Combs radiooncologist at the University of Heidelberg was awarded the Hermann Holthusen Prize for her achievements in improving the treatment of malignant brain tumours. The prize which comes with a purse of 5000 euros is the most prestigious prize in the field of radiooncology in Germany. Dr. Combs received the prize from the German Society of Radiooncology DEGRO at its annual meeting held in Magdeburg in June 2010. Dr. Combs most…https://www.gesundheitsindustrie-bw.de/en/article/press-release/stephanie-combs-excellent-research-on-the-treatment-of-brain-tumours
Press release - 22/06/2010 CureVac starts Phase IIa with mRNA immunotherapeutic in Non-Small Cell Lung Cancer CureVac GmbH, the mRNA company, today announced that the Paul-Ehrlich-Institute, the German regulatory authority for medicinal products, has approved the start of a Phase IIa trial for CV9201 to treat Non-Small Cell Lung Cancer (NSCLC).https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-starts-phase-iia-with-mrna-immunotherapeutic-in-non-small-cell-lung-cancer
Press release - 02/06/2010 immatics enters Collaboration with the National Cancer Institute (NCI) immatics biotechnologies GmbH announced on June 2nd, 2010 that it has signed a Clinical Trial Agreement with the Center for Cancer Research (CCR), National Cancer Institute (NCI), USA. The Agreement covers the clinical development of immatics’ therapeutic cancer vaccine IMA950 which is to be evaluated in the field of brain cancer, specifically glioblastoma, the most aggressive form of brain cancer. https://www.gesundheitsindustrie-bw.de/en/article/press-release/immatics-enters-collaboration-with-the-national-cancer-institute-nci
Press release - 14/05/2010 Viruses against cancer: complete regression of malignant brain tumours after treatment with parvoviruses Studies by scientists from the German Cancer Research Centre (DKFZ) have shown that advanced glioblastomas regressed completely in rats after treatment with parvoviruses, thus significantly increasing the survival time compared with untreated animals. Parvoviruses do not cause any disease symptoms in humans and the rats treated did not show any undesired side effects, either. A clinical phase I trial on parvovirus treatment of patients with…https://www.gesundheitsindustrie-bw.de/en/article/press-release/viruses-against-cancer-complete-regression-of-malignant-brain-tumours-after-treatment-with-parvoviru
Press release - 23/04/2010 Ernst & Young: "German Biotechnology Report 2010" During the global crisis in 2009, the revenues, number of companies and the number of employees in the German biotechnology industry remained unchanged from the previous year. However, considerable progress was made in terms of product development and market admissions. As in the previous year, 2009 saw a strong slump in terms of equity financing. Investments in research and developments fell. Collaborations and strategic alliances acted as…https://www.gesundheitsindustrie-bw.de/en/article/press-release/ernst-young-german-biotechnology-report-2010
Press release - 15/04/2010 Nycomed and Baxter receive FDA approval for TachoSil® Today Nycomed and its partner Baxter International Inc. NYSE BAX received the approval for TachoSil a surgical patch from the US Food and Drug Administration FDA. TachoSil has been approved as an adjunct to haemostasis control of bleeding in cardiovascular surgery. https://www.gesundheitsindustrie-bw.de/en/article/press-release/nycomed-and-baxter-receive-fda-approval-for-tachosil
Press release - 12/03/2010 mtm laboratories announces the European launch of CINtec® PLUS mtm laboratories, a privately held diagnostics company from Heidelberg, Germany, announced the launch of CINtec® PLUS, the company’s next generation cervical cancer screening product with unmatched accuracy for the screening and management for cervical cancer. CINtec® PLUS will be launched with claims direct in Germany, Italy, Spain, France and the UK, and will also be available in other parts of the world via mtm’s nominated distributors.https://www.gesundheitsindustrie-bw.de/en/article/press-release/mtm-laboratories-announces-the-european-launch-of-cintec-plus
Press release - 18/02/2010 New molecules promise improved diagnosis of pancreatic cancer Being diagnosed with pancreatic cancer is often a death sentence. One reason for the high mortality rate of pancreatic cancer patients is that there is currently no reliable diagnosis of early stages and no cure once the disease has reached a late stage. In an EU-funded project, 23 research groups from six countries have developed new strategies for the improved diagnosis of pancreatic cancer. Researchers at the Ulm-based Hospital for Nuclear…https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-molecules-promise-improved-diagnosis-of-pancreatic-cancer
Press release - 26/01/2010 Apogenix Initiates Clinical Phase II Study with its Lead Compound APG101 in Glioblastoma Apogenix GmbH, a biopharmaceutical company today announced the start of a clinical Phase II trial with its lead compound AGP101 in Glioblastoma Multiforme (GBM). The first patient has been treated with APG101 since December 2009 at the University Hospital in Heidelberg, Germany. https://www.gesundheitsindustrie-bw.de/en/article/press-release/apogenix-initiates-clinical-phase-ii-study-with-its-lead-compound-apg101-in-glioblastoma
Article - 25/01/2010 Hope for effective ulcerative colitis treatment Ulcerative colitis, a chronic form of inflammatory bowel disease, is characterised by a reduced amount of the lipid phosphatidylcholine in the colon mucosa. This fact was discovered by Wolfgang Stremmel and his team at the University Hospital of Heidelberg. In collaboration with the Heidelberg-based biotechnology company Lipid Therapeutics, the researchers are now working on the development of a phosphatidylcholine drug for the treatment of this…https://www.gesundheitsindustrie-bw.de/en/article/news/hope-for-effective-ulcerative-colitis-treatment
Article - 25/01/2010 Intelligent use of suitable biomarkers How quickly does a pharmaceutical substance exert its effect? What mechanisms does it use to exert its effect on people and how long does it remain active? In a team headed by Prof. Dr. Martin Elmlinger Nycomed GmbH has developed an efficient biomarker discovery concept specially adapted to the companys requirements and designed to clarify such questions. The concept is specifically geared to the phases and requirements of the companys projects.…https://www.gesundheitsindustrie-bw.de/en/article/news/intelligent-use-of-suitable-biomarkers
Article - 18/01/2010 New substance helps PKU patients enjoy food For many decades, a special low-protein (low-phenylalanine) diet has been the only way of treating children suffering from phenylketonuria (PKU) that effectively prevents them from developing severe impairments in mental function. However, this type of diet is not very tasty and it is often difficult to get children to cooperate. A paediatrician from Reutlingen, Prof. Dr. Friedrich Trefz, has now been able to show that the substance sapropterin…https://www.gesundheitsindustrie-bw.de/en/article/news/new-substance-helps-pku-patients-enjoy-food
Press release - 13/11/2009 Single molecules under the laser: How the genetic material is unwrapped The genetic material found in cells is not in its free state, but is bound to large protein complexes and tightly wrapped. To activate genes that could well play a role in carcinogenesis, the genetic material first needs to be unwrapped and made accessible to other cell components. Using a new biophysical method called single molecule spectroscopy, scientists from the “Biophysics of Macromolecules” division at the German Cancer Research Centre…https://www.gesundheitsindustrie-bw.de/en/article/press-release/single-molecules-under-the-laser-how-the-genetic-material-is-unwrapped
Press release - 11/11/2009 Hematopoietic stem cell treatment with a new gene therapy vector: A first success treating a brain disease Two children with adrenoleukodystrophy (ALD), a fatal brain disease, have been successfully treated with a new gene therapy vector. Two years after treatment, the disease evolution has been stopped, and no adverse effect of the gene therapy has been observed so far. The results of this clinical trial conducted by Drs Nathalie Cartier and Patrick Aubourg (Inserm, France) in collaboration with European partners have just been published in Science…https://www.gesundheitsindustrie-bw.de/en/article/press-release/hematopoietic-stem-cell-treatment-with-a-new-gene-therapy-vector-a-first-success-treating-a-brain-di
Press release - 05/11/2009 Canadian companies to establish contacts with potential Baden-Württemberg partners At a Canadian-German partnering event held on 29th October 2009 in Stuttgart, a number of Canadian and German companies presented themselves to an audience of representatives from industry, business associations and politics. The partnering event was jointly organised by the Canadian Consulate and BIOPRO Baden-Württemberg.https://www.gesundheitsindustrie-bw.de/en/article/press-release/canadian-companies-to-establish-contacts-with-potential-baden-wuerttemberg-partners
Press release - 21/10/2009 Meyenburg Award 2009 for the First Targeted Anti-Cancer Drug The 2009 Meyenburg Award for Cancer Research with an award sum of 50,000 euros goes to American blood cancer expert, Brian Druker. The Meyenburg Foundation honors Druker as a pioneer of molecularly targeted cancer therapies for developing the leukemia drug Imatinib (Gleevec). Druker’s work has turned chronic myeloid leukemia from a deathly threat into a treatable disease for many patients today. The Meyenburg-Award has been presented on…https://www.gesundheitsindustrie-bw.de/en/article/press-release/meyenburg-award-2009-for-the-first-targeted-anti-cancer-drug
Press release - 19/10/2009 New ulcerative colitis therapy in sight Lipid Therapeutics GmbH and Dr. Falk Pharma GmbH announced on 30th, September, that they have entered into a co-development and licensing agreement for LT-02. Under the terms of the agreement, Dr. Falk Pharma will receive exclusive access to the European rights to Lipid Therapeutics’ lead product LT-02 for the treatment of ulcerative colitis. Ulcerative colitis is a severe inflammation of the colon affecting more than one million people…https://www.gesundheitsindustrie-bw.de/en/article/press-release/new-ulcerative-colitis-therapy-in-sight
Press release - 18/09/2009 Affimed Therapeutics AG receives FDA Orphan Drug Designation for AFM13 against Hodgkin Lymphoma Affimed Therapeutics AG announced today that the US Food and Drug Administration (FDA) has granted orphan drug designation to the human recombinant antibody AFM13 for the treatment of Hodgkin lymphoma. The designation entitles Affimed to seven-year market exclusivity in the US upon approval of this drug candidate. AFM13 is a novel, bispecific antibody based on Affimed's proprietary TandAb technology.https://www.gesundheitsindustrie-bw.de/en/article/press-release/affimed-therapeutics-ag-receives-fda-orphan-drug-designation-for-afm13-against-hodgkin-lymphoma
Press release - 18/09/2009 Why don’t brain tumours respond to drugs? Malignant brain tumours do not often respond to promising new drugs. Researchers from Heidelberg have now uncovered a mechanism and a tumour marker that are linked to the development of this resistance. A “death receptor” might possibly indicate the chances of success of chemotherapy at the same time as providing new approaches for developing a new therapy for the successful treatment of brain tumours.https://www.gesundheitsindustrie-bw.de/en/article/press-release/why-don-t-brain-tumours-respond-to-drugs
Article - 21/08/2009 Patenting and clinical trials go hand in hand Back when he was doing his degree thesis at the German Cancer Research Centre in Heidelberg the immunologist Prof. Peter Öhlschläger who now works at the University of Constance laid down the basic principles for developing an artificial gene for the treatment of cervical cancer. Prof. Öhlschläger is currently in the process of filing a patent for DNA vaccines for HPV. In the following interview the scientist says that the greatest challenges are…https://www.gesundheitsindustrie-bw.de/en/article/news/patenting-and-clinical-trials-go-hand-in-hand
Press release - 30/07/2009 Boehringer Ingelheim set to outpace the market again After a successful start of the 2009 business year, Boehringer Ingelheim is expecting their sales growth to outpace the world pharmaceutical market; for the tenth time in succession. As announced by this second-largest German pharmaceuticals producer, the company posted growth in local currency (+ 8.3 per cent) over the previous year in the first six months of 2009. Net sales amounted to 6,388 million euro.https://www.gesundheitsindustrie-bw.de/en/article/press-release/boehringer-ingelheim-set-to-outpace-the-market-again